Cancer
Video-Assisted Thoracoscopy Surgery Lowers Mortality by 21% Compared to Lobectomy
Minimally Invasive Surgery in Early-Stage Lung Cancer Demonstrates Significant Survival Advantage Over Traditional Methods Barcelona, Spain – In a landmark...
Phase III Trial Shows Hypofractionated Radiotherapy Plus Chemotherapy Matches Survival Rates and Reduces Toxicity Compared to Conventional Treatment in Limited-Stage SCLC
(Barcelona, Spain — September 8, 2025) — A pivotal multi-center, randomized phase III clinical trial has recently demonstrated that a...
UK Study Finds Lung Cancer Screening Benefits Adults Up to Age 80 Who Are Surgical Candidates
(Barcelona, Spain, September 8, 2025, 10:45 a.m. CEST / UTC +2) — Recent findings presented at the prestigious International Association...
NADIM ADJUVANT Trial Highlights Advantages of Chemo-Immunotherapy After Surgery in Stage IB–IIIA NSCLC
Interim findings from the NADIM ADJUVANT Phase III clinical trial conducted by the Spanish Lung Cancer Group (GECP) have unveiled...
Do Early-Stage Cancer Surgery Patients Face Risk of Long-Term Opioid Use?
New insights into the complex dynamics of opioid use following curative-intent cancer surgery reveal a concerning trend in long-term opioid...
Promising Outcomes from First-in-Human Trial of DLL3-Targeted Antibody-Drug Conjugate SHR-4849 in Relapsed Small Cell Lung Cancer
First-in-Human Trial Highlights Breakthrough DLL3-Targeted Therapy for Relapsed Small Cell Lung Cancer In a landmark development in the treatment of...
Phase 2 IDeate-Lung01 Trial Shows Ifinatamab Deruxtecan Achieves High Response Rates in Previously Treated Extensive-Stage Small Cell Lung Cancer
In a groundbreaking advancement for small cell lung cancer (SCLC) therapy, recent data unveiled at the International Association for the...
Zidesamtinib Demonstrates Lasting Efficacy in ROS1 TKI-Pretreated NSCLC, Including Cases with CNS Involvement and ROS1 G2032R Mutations
In a groundbreaking advancement for the treatment of ROS1-positive non-small cell lung cancer (NSCLC), a novel investigational agent, zidesamtinib, has...
Crizotinib Does Not Enhance Disease-Free Survival in Resected Early-Stage ALK-Positive NSCLC
In a significant development in the field of thoracic oncology, recent findings from the Phase 3 E4512 clinical trial have...
FLAURA2 Trial Demonstrates Enhanced Overall Survival with Osimertinib and Chemotherapy in EGFR-Mutated Advanced NSCLC
In a groundbreaking advancement within the realm of targeted oncology, the international cancer research community has witnessed compelling evidence supporting...
Ivonescimab Combined with Chemotherapy Enhances Progression-Free Survival in EGFR-Positive NSCLC Patients After Third-Generation EGFR-TKI Treatment
In a groundbreaking advancement for the management of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)...
Aumolertinib Combined with Chemotherapy Enhances Progression-Free Survival in NSCLC Patients Harboring EGFR and Tumor Suppressor Gene Alterations: Findings from the ACROSS 2 Phase III Trial
Groundbreaking Phase III Trial Demonstrates Superior Efficacy of Aumolertinib Plus Chemotherapy in Advanced EGFR-Mutant NSCLC In a pivotal advancement for...
Phase II Study Finds Iza-Bren Plus Osimertinib Achieves 100% Response Rate in EGFR-Mutated NSCLC
In a groundbreaking advancement for the treatment of non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations,...
Novel Antibody-Drug Conjugate Demonstrates Promising Efficacy in EGFR-Mutated NSCLC Patients
In a groundbreaking development presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on...
COMPEL Study Finds Adding Chemotherapy to Osimertinib After Progression Enhances Progression-Free Survival in EGFR-Mutated NSCLC
In a groundbreaking development in the treatment of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)...
Study Confirms Accuracy of AI Lung Cancer Risk Model Sybil in Predominantly Black Patients at Urban Safety-Net Hospital
In a groundbreaking development presented at the prestigious International Association for the Study of Lung Cancer 2025 World Conference on...
Microbiome’s Hidden Role in Early Tumor Development
In recent years, the intricate relationship between the human microbiome and cancer development has emerged as a focal point of...
Natural Medicines Target Tumor Blood Vessels to Halt Cancer Progression
Recent breakthroughs in oncology are reshaping how we approach the challenge of halting cancer progression, with a novel emphasis on...
Cutting-Edge Oncolytic Virus and Immunotherapy Synergies Herald New Era in Cancer Treatment
The landscape of cancer treatment is undergoing a profound transformation, driven in large part by the innovative integration of oncolytic...
Breakthroughs in In Vivo CAR T Cell Production Transforming Cancer Therapy
A Revolutionary Leap in Cancer Therapy: The Promise and Challenges of In Vivo CAR T Cell Production Chimeric Antigen Receptor...
